Report cover image

Amyloidosis Treatment Market by Type (Medication, Surgery), End-Users (Hospitals, Specialty Centers) - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 188 Pages
SKU # IRE18418282

Description

Amyloidosis Treatment Market by Type (Medication, Surgery), End-Users (Hospitals, Specialty Centers) - Global Forecast 2024-2030


The Amyloidosis Treatment Market size was estimated at USD 5.23 billion in 2023 and expected to reach USD 5.70 billion in 2024, at a CAGR 7.57% to reach USD 8.73 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Amyloidosis Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Amyloidosis Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Amyloidosis Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbvie, Inc., Acrotech Biopharma, Inc, Alexion Pharmaceuticals, Alnylam Pharmaceuticals Inc., Arcturus Therapeutics, Inc., Astellas Pharma, Inc., AstraZeneca PLC, Attralus, Inc., BridgeBio Pharma, Inc., Bristol-Myers Squibb Company, Corino Therapeutics, Inc., GlaxoSmithKline PLC, Ionis Pharmaceuticals, Inc., Johnson & Johnson Services Inc, Merck & Co., Inc., Neurimmune AG, Oncopeptides AB, Pfizer Inc., Proclara Biosciences Inc., Prothena Corporation PLC, Regeneron Pharmaceuticals Inc., SOM INNOVATION BIOTECH, SA,, Sorrento Therapeutics, Inc., Spectrum Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Amyloidosis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type

Medication

Chemotherapy
  • Targeted therapy

    Anti-Angiogenesis Therapy
  • Monoclonal Antibodies
  • Proteasome Inhibitors
  • Surgery

    Bone Marrow Transplantation/Stem Cell Transplantation
  • Organ Transplantation
  • End-Users

    Hospitals
  • Specialty Centers
  • Region

    Americas

    Argentina
  • Brazil
  • Canada
  • Mexico
  • United States

    California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas
  • Asia-Pacific

    Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam
  • Europe, Middle East & Africa

    Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom
    The report offers valuable insights on the following aspects:

    1. Market Penetration: It presents comprehensive information on the market provided by key players.
    2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
    3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
    4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
    5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
    The report addresses key questions such as:

    1. What is the market size and forecast of the Amyloidosis Treatment Market?
    2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Amyloidosis Treatment Market?
    3. What are the technology trends and regulatory frameworks in the Amyloidosis Treatment Market?
    4. What is the market share of the leading vendors in the Amyloidosis Treatment Market?
    5. Which modes and strategic moves are suitable for entering the Amyloidosis Treatment Market?


    Note: PDF & Excel + Online Access - 1 Year

    • Table of Contents

    188 Pages
    1. Preface
    1.1. Objectives of the Study
    1.2. Market Segmentation & Coverage
    1.3. Years Considered for the Study
    1.4. Currency & Pricing
    1.5. Language
    1.6. Limitations
    1.7. Assumptions
    1.8. Stakeholders
    2. Research Methodology
    2.1. Define: Research Objective
    2.2. Determine: Research Design
    2.3. Prepare: Research Instrument
    2.4. Collect: Data Source
    2.5. Analyze: Data Interpretation
    2.6. Formulate: Data Verification
    2.7. Publish: Research Report
    2.8. Repeat: Report Update
    3. Executive Summary
    4. Market Overview
    4.1. Introduction
    4.2. Amyloidosis Treatment Market, by Region
    5. Market Insights
    5.1. Market Dynamics
    5.1.1. Drivers
    5.1.1.1. Significant prevalence of amyloidosis among rising gigantic population
    5.1.1.2. Growing awareness about early diagnosis and amyloidosis treatments
    5.1.1.3. Robust research activities to develop novel amyloidosis drugs
    5.1.2. Restraints
    5.1.2.1. Issues related to high cost and reimbursement policies of amyloidosis treatments
    5.1.3. Opportunities
    5.1.3.1. Emergence of new treatment options for treating amyloidosis
    5.1.3.2. Rising investments to develop modernized healthcare infrastructure
    5.1.4. Challenges
    5.1.4.1. Complexities and risk associated with amyloidosis treatments
    5.2. Market Segmentation Analysis
    5.3. Market Trend Analysis
    5.4. Cumulative Impact of High Inflation
    5.5. Porter’s Five Forces Analysis
    5.5.1. Threat of New Entrants
    5.5.2. Threat of Substitutes
    5.5.3. Bargaining Power of Customers
    5.5.4. Bargaining Power of Suppliers
    5.5.5. Industry Rivalry
    5.6. Value Chain & Critical Path Analysis
    5.7. Regulatory Framework
    6. Amyloidosis Treatment Market, by Type
    6.1. Introduction
    6.2. Medication
    6.3.1. Chemotherapy
    6.3.2. Targeted therapy
    6.3.3.1. Anti-Angiogenesis Therapy
    6.3.3.2. Monoclonal Antibodies
    6.3.3.3. Proteasome Inhibitors
    6.3. Surgery
    6.4.1. Bone Marrow Transplantation/Stem Cell Transplantation
    6.4.2. Organ Transplantation
    7. Amyloidosis Treatment Market, by End-Users
    7.1. Introduction
    7.2. Hospitals
    7.3. Specialty Centers
    8. Americas Amyloidosis Treatment Market
    8.1. Introduction
    8.2. Argentina
    8.3. Brazil
    8.4. Canada
    8.5. Mexico
    8.6. United States
    9. Asia-Pacific Amyloidosis Treatment Market
    9.1. Introduction
    9.2. Australia
    9.3. China
    9.4. India
    9.5. Indonesia
    9.6. Japan
    9.7. Malaysia
    9.8. Philippines
    9.9. Singapore
    9.10. South Korea
    9.11. Taiwan
    9.12. Thailand
    9.13. Vietnam
    10. Europe, Middle East & Africa Amyloidosis Treatment Market
    10.1. Introduction
    10.2. Denmark
    10.3. Egypt
    10.4. Finland
    10.5. France
    10.6. Germany
    10.7. Israel
    10.8. Italy
    10.9. Netherlands
    10.10. Nigeria
    10.11. Norway
    10.12. Poland
    10.13. Qatar
    10.14. Russia
    10.15. Saudi Arabia
    10.16. South Africa
    10.17. Spain
    10.18. Sweden
    10.19. Switzerland
    10.20. Turkey
    10.21. United Arab Emirates
    10.22. United Kingdom
    11. Competitive Landscape
    11.1. FPNV Positioning Matrix
    11.2. Market Share Analysis, By Key Player
    11.3. Competitive Scenario Analysis, By Key Player
    12. Competitive Portfolio
    12.1. Key Company Profiles
    12.1.1. Abbvie, Inc.
    12.1.2. Acrotech Biopharma, Inc
    12.1.3. Alexion Pharmaceuticals
    12.1.4. Alnylam Pharmaceuticals Inc.
    12.1.5. Arcturus Therapeutics, Inc.
    12.1.6. Astellas Pharma, Inc.
    12.1.7. AstraZeneca PLC
    12.1.8. Attralus, Inc.
    12.1.9. BridgeBio Pharma, Inc.
    12.1.10. Bristol-Myers Squibb Company
    12.1.11. Corino Therapeutics, Inc.
    12.1.12. GlaxoSmithKline PLC
    12.1.13. Ionis Pharmaceuticals, Inc.
    12.1.14. Johnson & Johnson Services Inc
    12.1.15. Merck & Co., Inc.
    12.1.16. Neurimmune AG
    12.1.17. Oncopeptides AB
    12.1.18. Pfizer Inc.
    12.1.19. Proclara Biosciences Inc.
    12.1.20. Prothena Corporation PLC
    12.1.21. Regeneron Pharmaceuticals Inc.
    12.1.22. SOM INNOVATION BIOTECH, SA,
    12.1.23. Sorrento Therapeutics, Inc.
    12.1.24. Spectrum Pharmaceuticals, Inc.
    12.1.25. Takeda Pharmaceutical Company Limited
    12.2. Key Product Portfolio
    13. Appendix
    13.1. Discussion Guide
    13.2. License & Pricing
    FIGURE 1. AMYLOIDOSIS TREATMENT MARKET RESEARCH PROCESS
    FIGURE 2. AMYLOIDOSIS TREATMENT MARKET SIZE, 2023 VS 2030
    FIGURE 3. AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
    FIGURE 4. AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
    FIGURE 5. AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 6. AMYLOIDOSIS TREATMENT MARKET DYNAMICS
    FIGURE 7. AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
    FIGURE 8. AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 9. AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
    FIGURE 10. AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 11. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 12. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 13. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
    FIGURE 14. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 15. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 16. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 17. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 18. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 19. AMYLOIDOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
    FIGURE 20. AMYLOIDOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023

    Pricing

    Currency Rates
    How Do Licenses Work?

    How Do Licenses Work?

    The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

    • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

    • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

    • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

    • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

    • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

    License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

    Head shot

    Questions or Comments?

    Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
    Chat Now
    Contact Us